The treatment of choice for main-duct<unk> s is resection due to approximately 50% chance of malignancy. Side-branch<unk> s are occasionally monitored with regular CT or MRIs, but most are eventually resected, with a 30% rate of malignancy in these resected tumors. Indications for surgical resection include obstructive jaundice, an enhancing mural nodule >5 mm, and pancreatic duct dilation (>10 mm). Surgery can include the removal of the head of the pancreas (a pancreaticoduodenectomy), removal of the body and tail of the pancreas (a distal pancreatectomy), or rarely removal of the entire pancreas (a total pancreatectomy). In selected cases the surgery can be performed using minimally invasive techniques such as laparoscopy or robotic surgery. A study using Surveillance, Epidemiology, and End Results Registry (SEER) data suggested that increased lymph node counts harvested during the surgery were associated with better survival in invasive<unk>  patients.
Intraductal papillary mucinous neoplasm
Pancreatic mucinous cystic neoplasm
Pancreatic serous cystadenoma
Pancreatic pseudocyst
Bile duct hamartoma
Pancreatic mucinous cystadenoma
Collecting duct carcinoma
Phyllodes tumor